Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anti-Müllerian hormone type-2 receptor (AMHR2)
- Target
- AMHR2
- Molecular classification
- Receptor, Transforming growth factor beta (TGF-β) type II receptor family, Single-pass transmembrane protein
01
Overview
Anti-Müllerian hormone type-2 receptor (AMHR2) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β receptor superfamily. It is the dedicated type II receptor for anti-Müllerian hormone (AMH) and is vital for male sexual differentiation by mediating regression of the Müllerian ducts in the developing embryo. AMHR2 is essential for proper gonadal development and also regulates follicle recruitment in the adult ovary. The receptor is characterized structurally by a three-finger toxin fold in its extracellular domain, conferring selectivity for AMH binding. Variations or dysfunction in this receptor are associated with sexual development disorders and certain reproductive cancers. Currently, AMHR2 is under investigation as a therapeutic and diagnostic target, especially in rare reproductive cancers and fertility-related conditions[1][2][3].
- Other names
- Anti-Muellerian hormone type-2 receptorAMH type II receptorAMHRMISR2MISRIIMRIIMuellerian inhibiting substance type II receptorMIS type II receptoranti-Muellerian hormone type II receptorMullerian inhibiting substance type II receptor
02
Mechanism of action
Agonists or antagonists would modulate AMH signaling by binding to AMHR2 and altering downstream SMAD pathway activation Therapeutic antibodies might block or mimic AMH binding to the receptor
03
Biological functions
Signal transductionSexual differentiation (Müllerian duct regression)Regulation of folliculogenesis in femalesGonadal development
04
Disease associations
Cancer (notably ovarian and testicular cancers)Disorders of sexual development, such as persistent Müllerian duct syndromeReproductive disorders
05
Safety considerations
Potential for interference with reproductive development and fertilityTheoretical risk for hormonal disruption in off-target tissuesImpact on gonadal function as a result of pathway modulation
06
Interacting drugs
No FDA-approved drugs directly targeting AMHR2 as of 2025; antibody candidates and experimental agents are in preclinical/clinical development
07
Biomarkers
AMHR2 expression (by immunohistochemistry or molecular assays) to aid identification of ovarian/testicular malignanciesAMH serum levels (reflecting AMHR2 pathway function, especially in fertility assessments)
Beyond the preview
Go deeper on Anti-Müllerian hormone type-2 receptor (AMHR2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-Müllerian hormone type-2 receptor (AMHR2).